Recruiting soon

AZD6234 Bioavailability in Overweight or Obesity

Study Aim

This study aims to evaluate how the body absorbs AZD6234 in adults who are overweight or obese.

What is being tested

AZD6234 Formulation 1

+ AZD6234 Formulation 2 (low concentration)

+ AZD6234 Formulation 2 (high concentration)

Drug

Who is being recruted

Body Weight+5

+ Nutrition Disorders

+ Nutritional and Metabolic Diseases

From 18 to 55 Years

+14 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Treatment Study

Phase 1

Interventional

Study Start: November 2025

See protocol details

Summary

Principal SponsorAstraZeneca

Study ContactAstraZeneca Clinical Study Information Center

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Study start date: November 10, 2025

Actual date on which the first participant was enrolled.

This clinical trial is designed to explore how different versions of a medication called AZD6234 are absorbed in the body when given to people who are overweight or obese. The trial also looks at any side effects that might occur. Understanding how the body processes these various formulations of AZD6234 can help in developing effective treatments for managing weight-related health issues. This study is important because it could lead to better strategies for dealing with obesity, which is a significant health challenge affecting many people today. Participants in the study, consisting of 21 healthy individuals aged 18 to 55, will receive injections of the medication into their abdomen. This will occur over four different treatment periods. During each period, participants will stay at the clinic in Nottingham, UK, for six nights. The trial includes returning for up to ten outpatient visits and can last up to 19 weeks in total. Blood and urine samples will be regularly collected to measure how much of the medication and its breakdown products are present in the body, check for any side effects, and see how the immune system responds. This helps researchers understand both the safety and the effectiveness of the different formulations of AZD6234.

Official TitleA Phase I, Single-Dose, Open-Label, Sequential, Randomised, Crossover Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD6234 in Participants Living With Overweight or Obesity

NCT07220954

Principal SponsorAstraZeneca

Study ContactAstraZeneca Clinical Study Information Center

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

21 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Conditions

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 55 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Body WeightNutrition DisordersNutritional and Metabolic DiseasesObesitySigns and SymptomsPathological Conditions, Signs and SymptomsOvernutritionOverweight

Criteria

2 inclusion criteria required to participate

Healthy males or non-pregnant, non-lactating females aged 18 to 55 years inclusive

BMI of 25.0 to 35.0 kg/m2 inclusive and weight ≥50 kg

12 exclusion criteria prevent from participating

History of any clinically important disease or disorder

History or presence of clinically significant cardiovascular, renal, hepatic, dermatological, respiratory, neurological, psychiatric or gastrointestinal disorder including a history of pancreatitis or gall stones

Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the planned first dosing day

Clinically significant abnormal clinical chemistry, haematology, coagulation or urinalysis

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.

Treatment Groups

Study Objectives

3 intervention groups are designated in this study

This study does not include a placebo group

Treatment Groups

Group I

Experimental

Participants will receive a single SC injection of AZD6234 in each of four study periods, Treatment A in Period 1, Treatment B in Period 2, Treatment C in Period 3 and Treatment D in Period 4 (Where A is AZD6234 Formulation 1, B is AZD6234 Formulation 2 (low concentration), C is AZD6234 Formulation 2 (high concentration) and D is AZD6234 Formulation 3)

Group II

Experimental

Participants will receive a single SC injection of AZD6234 in each of four study periods, Treatment B in Period 1, Treatment C in Period 2, Treatment A in Period 3 and Treatment D in Period 4 (Where A is AZD6234 Formulation 1, B is AZD6234 Formulation 2 (low concentration), C is AZD6234 Formulation 2 (high concentration) and D is AZD6234 Formulation 3)

Group III

Experimental

Participants will receive a single SC injection of AZD6234 in each of four study periods, Treatment C in Period 1, Treatment A in Period 2, Treatment B in Period 3 and Treatment D in Period 4 (Where A is AZD6234 Formulation 1, B is AZD6234 Formulation 2 (low concentration), C is AZD6234 Formulation 2 (high concentration) and D is AZD6234 Formulation 3)

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Research Site

Ruddington, United KingdomOpen Research Site in Google Maps

Recruiting soonOne Study Center